Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Penile Cancer Research from the Bench Side to...
share announcement

Advances in Penile Cancer Research from the Bench Side to the Patients

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 4020

Special Issue Editors

Dr. Jad Chahoud

E-Mail Website
Guest Editor
Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Interests: penile cancer; renal cell cancer; HPV-related cancers
Dr. Philippe E. Spiess

E-Mail Website
Guest Editor
Department of GU Oncology and Tumor Biology, Moffitt Cancer Center, Tampa, FL, USA
Interests: bladder cancer; kidney (renal cell) cancer; penile cancer; testicular cancer

Special Issue Information

Dear Colleagues,

Penile cancer is a rare and deadly cancer that affects more than 30,000 patients around the globe every year. Over the past two decades we have seen limited improvement in the clinical outcomes of patients with advanced penile cancer.

In this Special Issue we aim to highlight all advances, covering benchside to bedside efforts, that have been made in penile cancer, in hope of improving the clinical outcomes of patients with this rare and challenging cancer.

We aim to include papers focusing on advances in preclinical specific penile cancer models as well as molecular, viral, and immune pathways related to penile cancer oncogenesis that have led to our better understanding of the disease development.

We will also include papers highlighting advances in chemotherapies, vaccine, as well as immune-based and targeted therapies for patients with localized and advanced penile cancer. Papers highlighting advances in radiation and surgical therapies will be welcomed.

Finally, we will showcase research focused on patient-centered approaches with advances in patient-reported outcome and quality-of-life research.

Dr. Jad Chahoud
Dr. Philippe E. Spiess
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • penile cancer
  • preclinical models and systems
  • tumor–microenvironment interaction
  • targeted therapies
  • vaccine therapies
  • immune-based therapies
  • molecular pathways immune pathways
  • clinical trials
  • HPV oncogenesis
  • patient-reported outcomes and quality of life

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 3988 KiB  
Article
Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage
by Filip Ionescu, Jonathan Nguyen, Carlos Moran Segura, Mahati Paravathaneni, G. Daniel Grass, Peter Johnstone, Niki M. Zacharias, Curtis A. Pettaway, Xin Lu, Youngchul Kim, Junmin Whiting, Jasreman Dhillon, Steven A. Eschrich, Juskaran Chadha, Keerthi Gullapalli, Gabriel Roman Souza, Hiroko Miyagi, Brandon J. Manley, Philippe E. Spiess and Jad Chahoud
Cancers 2024, 16(2), 303; https://doi.org/10.3390/cancers16020303 - 11 Jan 2024
Viewed by 854
Abstract
Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a [...] Read more.
Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a subset of patients suggests immune escape may play an important role in tumorigenesis. Herein, we explored for the first time the immune microenvironment of 57 men with PSCC and how it varies with the presence of human papillomavirus (HPV) infection and across tumor stages using multiplex immunofluorescence of key immune cell markers. We observed an increase in the density of immune effector cells in node-negative tumors and a progressive rise in inhibitory immune players such as type 2 macrophages and upregulation of the PD-L1 checkpoint in men with N1 and N2-3 disease. There were no differences in immune cell densities with HPV status. Full article
(This article belongs to the Special Issue Advances in Penile Cancer Research from the Bench Side to the Patients)
►▼ Show Figures

Figure 1

15 pages, 8112 KiB  
Article
An Assessment of the Penile Squamous Cell Carcinoma Surfaceome for Biomarker and Therapeutic Target Discovery
by George Daniel Grass, Dalia Ercan, Alyssa N. Obermayer, Timothy Shaw, Paul A. Stewart, Jad Chahoud, Jasreman Dhillon, Alex Lopez, Peter A. S. Johnstone, Silvia Regina Rogatto, Philippe E. Spiess and Steven A. Eschrich
Cancers 2023, 15(14), 3636; https://doi.org/10.3390/cancers15143636 - 15 Jul 2023
Viewed by 1263
Abstract
Penile squamous cell carcinoma (PSCC) is a rare malignancy in most parts of the world and the underlying mechanisms of this disease have not been fully investigated. About 30–50% of cases are associated with high-risk human papillomavirus (HPV) infection, which may have prognostic [...] Read more.
Penile squamous cell carcinoma (PSCC) is a rare malignancy in most parts of the world and the underlying mechanisms of this disease have not been fully investigated. About 30–50% of cases are associated with high-risk human papillomavirus (HPV) infection, which may have prognostic value. When PSCC becomes resistant to upfront therapies there are limited options, thus further research is needed in this venue. The extracellular domain-facing protein profile on the cell surface (i.e., the surfaceome) is a key area for biomarker and drug target discovery. This research employs computational methods combined with cell line translatomic (n = 5) and RNA-seq transcriptomic data from patient-derived tumors (n = 18) to characterize the PSCC surfaceome, evaluate the composition dependency on HPV infection, and explore the prognostic impact of identified surfaceome candidates. Immunohistochemistry (IHC) was used to validate the localization of select surfaceome markers. This analysis characterized a diverse surfaceome within patient tumors with 25% and 18% of the surfaceome represented by the functional classes of receptors and transporters, respectively. Significant differences in protein classes were noted by HPV status, with the most change being seen in transporter proteins (25%). IHC confirmed the robust surface expression of select surfaceome targets in the top 85% of expression and a superfamily immunoglobulin protein called BSG/CD147 was prognostic of survival. This study provides the first description of the PSCC surfaceome and its relation to HPV infection and sets a foundation for novel biomarker and drug target discovery in this rare cancer. Full article
(This article belongs to the Special Issue Advances in Penile Cancer Research from the Bench Side to the Patients)
►▼ Show Figures

Figure 1

Other

Jump to: Research

13 pages, 991 KiB  
Systematic Review
The Prognostic Role of Human Papillomavirus and p16 Status in Penile Squamous Cell Carcinoma—A Systematic Review
by Kevin Parza, Arfa Mustasam, Filip Ionescu, Mahati Paravathaneni, Reagan Sandstrom, Houssein Safa, G. Daniel Grass, Peter A. Johnstone, Steven A. Eschrich, Juskaran Chadha, Niki Zacharias, Curtis A. Pettaway, Philippe E. Spiess and Jad Chahoud
Cancers 2023, 15(14), 3713; https://doi.org/10.3390/cancers15143713 - 21 Jul 2023
Cited by 4 | Viewed by 1169
Abstract
PSCC is a rare cancer, with approximately half of all cases related to HPV. While HPV and p16 IHC testing have proven their prognostic value for oropharyngeal cancer, this is not yet established for PSCC. The current level of evidence exploring the relation [...] Read more.
PSCC is a rare cancer, with approximately half of all cases related to HPV. While HPV and p16 IHC testing have proven their prognostic value for oropharyngeal cancer, this is not yet established for PSCC. The current level of evidence exploring the relation between PSCC and HPV is moderate, so we conducted a systematic review following PRISMA guidelines to evaluate the prognostic role of HPV and p16 IHC in PSCC clinical outcomes. We searched the PubMed, Embase, and Cochrane databases and identified 34 relevant studies that met our inclusion criteria. Of these, 33 were retrospective cohort studies, and one was a cross-sectional study. Nine studies reported that HPV-positive and p16-positive PSCC had better overall survival (OS) and disease-free survival (DFS). This study highlights the need for a meta-analysis to determine the role of routine HPV status or p16 staining testing as part of the initial diagnosis and staging of PSCC patients worldwide. Full article
(This article belongs to the Special Issue Advances in Penile Cancer Research from the Bench Side to the Patients)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop